Dr. Reddy’s Laboratories Q4 Results: Net profit falls 86% YoY to Rs 220.5 crore, revenue down 11.6%

Dr. Reddy’s Laboratories reported a weak performance for the fourth quarter ended March 2026, with profit and revenue declining on a year-on-year (YoY) basis. The company’s earnings were impacted by lower operating performance and higher expenses during the quarter.

The pharma major posted a net profit of ₹220.5 crore in Q4FY26, down 86.1% compared to ₹1,587.3 crore reported in the corresponding quarter last year.

Revenue from operations stood at ₹7,516.2 crore during the March quarter, compared to ₹8,506 crore in Q4FY25, registering a decline of 11.6% YoY.

Gross profit for the quarter came in at ₹3,369.1 crore versus ₹4,726.3 crore a year ago, reflecting a sharp decline of 28.7%.

Total operating expenses increased to ₹3,236.6 crore from ₹2,961.6 crore in the same period last year, marking a rise of 9.3% YoY.

Research and development (R&D) expenses declined 24.7% YoY to ₹546.3 crore compared to ₹725.8 crore in Q4FY25.

The company reported profit before tax (PBT) of ₹199.1 crore for the quarter, plunging 90.1% from ₹2,005.4 crore reported in the year-ago period.

Finance income stood at ₹167.7 crore, down 44.2% YoY, while finance expense increased 61.1% to ₹105.7 crore during the quarter.